Resveratrol ameliorates hyperglycemia-induced renal tubular oxidative stress damage via modulating the SIRT1/FOXO3a pathway

Diabetes Research and Clinical Practice

Volumn 126, Issue , 2017, Pages 172-181

  Wang, Xueling ^a   Meng, Linghang ^a   Zhao, Long ^a   Wang, Zengfu ^b   Liu, Haiying ^a   Liu, Gang ^a   Guan, Guangju ^a  

^a SHANDONG UNIVERSITY   (China)

^b Department of Otolaryngology   (China)

Author keywords

Deacetylation; Diabetic nephropathy; FOXO3a; Oxidative stress; Resveratrol; SIRT1

Indexed keywords

CATALASE; GLUCOSE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR FKHRL1; FOXO3A PROTEIN, RAT; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY TUBULE; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; ANIMAL; CELL PROTECTION; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; CATALASE; CYTOPROTECTION; DIABETIC NEPHROPATHIES; FORKHEAD BOX PROTEIN O3; HYPERGLYCEMIA; KIDNEY TUBULES; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; SUPEROXIDE DISMUTASE;

EID: 85014110703     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.12.005     Document Type: Article

References (44)

1. [1] Gilbert, R.E., Cooper, M.E., The tubulointerstitium in progressive diabetic kidney disease more than an aftermath of glomerular injury?. Kidney Int, 1999, 1627–1637.
2. [2] Kanwar, Y.S., Sun, L., Xie, P., Liu, F.Y., Chen, S., A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Ann Rev Pathol 6 (2011), 395–423.
3. [3] Hasegawa, K., Wakino, S., Simic, P., Sakamaki, Y., Minakuchi, H., Fujimura, K., et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med 19 (2013), 1496–1504.
4. [4] Wagener, F.A., Dekker, D., Berden, J.H., Scharstuhl, A., van der Vlag, J., The role of reactive oxygen species in apoptosis of the diabetic kidney. Apoptosis 14 (2009), 1451–1458.
5. [5] Forbes, J.M., Coughlan, M.T., Cooper, M.E., Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57 (2008), 1446–1454.
6. [6] Ha, H., Hwang, I.A., Park, J.H., Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 82:Suppl 1 (2008), S42–S45.
7. [7] Bleyer, A.J., Fumo, P., Snipes, E.R., Goldfarb, S., Simmons, D.A., Ziyadeh, F.N., Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule. Kidney Int 45 (1994), 659–666.
8. [8] Hou, S., Zheng, F., Li, Y., Gao, L., Zhang, J., The protective effect of glycyrrhizic acid on renal tubular epithelial cell injury induced by high glucose. Int J Mol Sci 15 (2014), 15026–15043.
9. [9] Allen, D.A., Harwood, S., Varagunam, M., Raftery, M.J., Yaqoob, M.M., High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases. FASEB J 17 (2003), 908–910.
10. [10] Verzola, D., Bertolotto, M.B., Villaggio, B., Ottonello, L., Dallegri, F., Frumento, G., et al. Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells. J Investig Med 50 (2002), 443–451.
11. [11] Palsamy, P., Subramanian, S., Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta 1812 (2011), 719–731.
12. [12] Nemoto, S., Finkel, T., Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295 (2002), 2450–2452.
13. [13] Giannakou, M.E., Partridge, L., The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 14 (2004), 408–412.
14. [14] Kobayashi, Y., Furukawa-Hibi, Y., Chen, C., Horio, Y., Isobe, K., Ikeda, K., et al. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med 16 (2005), 237–243.
15. [15] Brunet, A., Sweeney, L.B., Sturgill, J.F., Chua, K.F., Greer, P.L., Lin, Y., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303 (2004), 2011–2015.
16. [16] Leonard, S.S., Xia, C., Jiang, B.H., Stinefelt, B., Klandorf, H., Harris, G.K., et al. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309 (2003), 1017–1026.
17. [17] Pervaiz, S., Holme, A.L., Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 11 (2009), 2851–2897.
18. [18] Lv, S., Cheng, J., Sun, A., Li, J., Wang, W., Guan, G., et al. Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting oxidative stress. Diabetes Res Clin Pract 104 (2014), 143–154.
19. [19] Tesch, G.H., Allen, T.J., Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 12 (2007), 261–266.
20. [20] Brownlee, M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005), 1615–1625.
21. [21] Chung, S.S., Ho, E.C., Lam, K.S., Chung, S.K., Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 14 (2003), S233–S236.
22. [22] Ha, H., Yu, M.R., Kim, K.H., Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radical Biol Med 26 (1999), 944–950.
23. [23] Craven, P.A., DeRubertis, F.R., Kagan, V.E., Melhem, M., Studer, R.K., Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-beta, and glomerular size in diabetes. J Am Soc Nephrol 8 (1997), 1405–1414.
24. [24] Kitada, M., Kume, S., Takeda-Watanabe, A., Kanasaki, K., Koya, D., Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond) 124 (2013), 153–164.
25. [25] Pallas, M., Pizarro, J.G., Gutierrez-Cuesta, J., Crespo-Biel, N., Alvira, D., Tajes, M., et al. Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience 154 (2008), 1388–1397.
26. [26] Palsamy, P., Sivakumar, S., Subramanian, S., Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. Chem Biol Interact 186 (2010), 200–210.
27. [27] Webster, B.R., Lu, Z., Sack, M.N., Scott, I., The role of sirtuins in modulating redox stressors. Free Radical Biol Med 52 (2012), 281–290.
28. [28] Kops, G.J., Dansen, T.B., Polderman, P.E., Saarloos, I., Wirtz, K.W., Coffer, P.J., et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419 (2002), 316–321.
29. [29] Hasegawa, K., Wakino, S., Yoshioka, K., Tatematsu, S., Hara, Y., Minakuchi, H., et al. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun 372 (2008), 51–56.
30. [30] Yun, J.M., Chien, A., Jialal, I., Devaraj, S., Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem 23 (2012), 699–705.
31. [31] Holthoff, J.H., Wang, Z., Seely, K.A., Gokden, N., Mayeux, P.R., Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int 81 (2012), 370–378.
32. [32] Xu, Y., Nie, L., Yin, Y.G., Tang, J.L., Zhou, J.Y., Li, D.D., et al. Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells. Toxicol Appl Pharmacol 259 (2012), 395–401.
33. [33] Liu, M.H., Yuan, C., He, J., Tan, T.P., Wu, S.J., Fu, H.Y., et al. Resveratrol protects PC12 cells from high glucose-induced neurotoxicity via PI3K/Akt/FoxO3a pathway. Cell Mol Neurobiol 35 (2015), 513–522.
34. [34] Hori, Y.S., Kuno, A., Hosoda, R., Horio, Y., Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One, 8, 2013, e73875.
35. [35] Tan, W.Q., Wang, K., Lv, D.Y., Li, P.F., Foxo3a inhibits cardiomyocyte hypertrophy through transactivating catalase. J Biol Chem 283 (2008), 29730–29739.
36. [36] Venkatesan, B., Mahimainathan, L., Das, F., Ghosh-Choudhury, N., Ghosh Choudhury, G., Downregulation of catalase by reactive oxygen species via PI 3 kinase/Akt signaling in mesangial cells. J Cell Physiol 211 (2007), 457–467.
37. [37] Kato, M., Yuan, H., Xu, Z.G., Lanting, L., Li, S.L., Wang, M., et al. Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol 17 (2006), 3325–3335.
38. [38] Imai, S., Guarente, L., Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci 31 (2010), 212–220.
39. [39] van der Horst, A., Burgering, B.M., Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 8 (2007), 440–450.
40. [40] Barthel, A., Schmoll, D., Unterman, T.G., FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab (TEM) 16 (2005), 183–189.
41. [41] Nemoto, S., Fergusson, M.M., Finkel, T., Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306 (2004), 2105–2108.
42. [42] Borra, M.T., Smith, B.C., Denu, J.M., Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280 (2005), 17187–17195.
43. [43] Beher, D., Wu, J., Cumine, S., Kim, K.W., Lu, S.C., Atangan, L., et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74 (2009), 619–624.
44. [44] Pacholec, M., Bleasdale, J.E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R.S., et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285 (2010), 8340–8351.